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M A J O R A R T I C L E
Continuous Infusion of Escalated
Doses of Amphotericin B Deoxycholate:
An Open-Label Observational Study
Alexander Imhof,1,a Roland B. Walter,1,2 and Andreas Schaffner1
1Department of Internal Medicine, Medical Clinic B, University Hospital, Zu¨rich, Switzerland; and 2Pediatric Oncology, Fred Hutchinson Cancer
Research Center, Seattle, Washington
(See the editorial commentary by Hiemenz on pages 952–3)
Amphotericin B deoxycholate (AmB-d) remains a mainstay of antifungal therapy for immunocompromised
patients, despite being associated with significant therapy-related toxicity. Because continuous infusion of
AmB-d is better tolerated than traditional administration over 2–6 hours, we evaluated escalation of the
AmB-d dose in 33 patients (31 of whom were neutropenic), for whom the initial dosage of AmB-d (1 mg/kg/
day) was gradually increased to 2.0 mg/kg/day when renal function remained stable and the drug was tolerated.
Dose escalation was possible without delay in 28 patients. Median duration of AmB-d therapy was 16 days
(range, 7–72 days). Infusion-related reactions accompanied !18% of AmB-d infusions. Twenty-seven patients
had a decrease in creatinine clearance while receiving AmB-d therapy. A 12-fold decrease in creatine clearance
was observed in 5 patients, and the decrease was dose-limiting in only 1 patient; no dialysis was required. In
conclusion, continuous infusion of AmB-d escalated to 2.0 mg/kg/day seems not to cause additional impairment
of vital organ functions and to be well tolerated by most patients.
The incidence of systemic opportunistic fungal infec-
tions has dramatically increased during the past 20
years, and, presently, opportunistic fungal infections
constitute a leading cause of morbidity and mortality
in neutropenic patients [1]. Despite advances in the
development of new agents, amphotericin B (AmB)
remains a cornerstone of antifungal therapy for patients
with opportunistic fungal infections. However, clinical
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use is hindered by the intrinsic toxicity of the molecule,
which causes dose-limiting organ dysfunction in some
cases, as well as the drug’s insolubility in water, which
requires addition of the detergent deoxycholate or lipids
for administration to humans. Although lipid formu-
lations are associated with fewer side effects, they are
expensive and are probably not more effective than
AmB deoxycholate (AmB-d) [2, 3].
Traditionally, AmB-d is given in 2–6 h infusions on
the basis of the assumption that the severity and fre-
quency of related side effects increases during more-
rapid administration. Nevertheless, daily doses of 11.0
mg/kg are usually not recommended, for reasons of
toxicity [4, 5]. Recently, continuous infusion of AmB-
d has been shown to reduce the incidence of nephro-
toxicity and infusion-related side effects, compared
with traditional administration of the same amount of
drug over 2–6 h [6, 7]. This finding suggests the pos-
sibility of further dose escalation, which might offer
therapeutic benefit, because clinical data from both
944 • CID 2003:36 (15 April) • Imhof et al.
Table 1. Basic demographic characteristics of and laboratory parameters for patients in a study of amphotericin B
deoxycholate (AmB-d) dose escalation.
Characteristic
All patients
(n p 33)
AmB-d target dosage group
1.5 mg/kg/day
(n p 14)
1.75 mg/kg/day
(n p 9)
2 mg/kg/day
(n p 10)
Age, median years (range) 54.4 (15.8–70.3) 55.0 (23.4–70.3) 42.7 (32.2–67.1) 40.9 (15.8–58.7)
Female sex, no. (%) of patients 15 (45) 7 (50) 4 (44) 4 (40)
Underlying condition, no. of patients
Acute myeloid leukemia 25 13 7 5
Hairy cell leukemia 1 1 — —
Acute lymphatic leukemia 2 — 1 1
Non-Hodgkin lymphoma 1 — — 1
Myelodysplastic syndrome 1 — 1 —
Solid tumor 1 — — 1
HIV infection 2 — — 2
Type of fungal infection
Proven 9 3 2 4
Probable 9 4 2 3
Possible 15 7 5 3
Baseline laboratory parameters,
median value (range)a
ANC, neutrophils/mL 30 (10–7250) 20 (10–470) 40 (10–110) 60 (10–7250)
Creatinine, mM 63 (44–95) 62 (53–94) 67 (44–95) 67 (54–92)
AST, U/L 20 (6–105) 20.5 (6–105) 26 (7–92) 18 (7–69)
ALT, U/L 31 (8–158) 26.5 (8–158) 22 (9–118) 44 (10–83)
Total bilirubin, mM 15 (3–40) 14 (9–22) 15 (6–28) 16.5 (3–40)
AP, U/L 74 (16–322) 92 (33–211) 81 (29–299) 69.5 (16–322)
Potassium, mM 3.7 (3.1–5.0) 3.6 (3.1–4.2) 3.8 (3.5–4.2) 3.9 (3.3–5.0)
Magnesium, mM 0.77 (0.65–0.95) 0.76 (0.65–0.95) 0.78 (0.56–0.85) 0.78 (0.68–0.87)
CRP, mg/L 111 (15–348) 106 (15–290) 220 (67–348) 74 (18–215)
Bicarbonate, mM 22.1 (19–28) 22 (20–27) 23 (19–28) 20 (19–27)
NOTE. ALT, alanine aminotransferase; ANC, absolute neutrophil count; AP, alkaline phosphatase; AST, aspartate aminotransferase; CRP,
C-reactive protein.
a Normal levels and ranges for laboratory values are as follows: creatinine, 70–105 mM; AST, !35 U/L; ALT, !35 U/L; total bilirubin, !25 mM;
AP, 30–115 U/L; potassium, 3.5–4.5 mM; magnesium, 0.65–1.0 mM; and CRP, !5 mg/L.
studies of humans and experiments with neutropenic animals
have indicated dose-dependent efficacy of AmB-d [8–11].
There is only scant knowledge, however, about the safety and
tolerance of dose-escalated AmB-d. These issues were addressed
in the present open-label, observational study, which involved
a cohort of adult immunocompromised patients, most of
whom had chemotherapy-induced neutropenia, to whom
AmB-d was given by continuous infusion for treatment of
proven, probable, or possible systemic fungal infection.
PATIENTS AND METHODS
Study population. All patients (age, 116 years) at our tertiary
care referral center for adult internal medicine (University Hos-
pital of Zurich, Switzerland), including those in the intensive
care unit, were eligible for the study if the treating physicians
considered treatment with AmB to be necessary. Exclusion cri-
teria were a calculated creatinine clearance of !30 mL/min [12],
an estimated duration of antifungal therapy of !7–10 days,
pregnancy or lactation, known AmB intolerance, or receipt of
systemic AmB treatment within the 12 months before enroll-
ment. The local ethics committee approved the study, and writ-
ten informed consent was obtained from all participants or
legally authorized representatives before study entry. The level
of probability of fungal infection was classified according to
definitions recently proposed by an international consensus
committee (table 1) [13].
Antifungal therapy. On day 1 of the study, 1 mg/kg of
AmB-d (Fungizone; Bristol-Myers Squibb) was administered
in 500 mL of 5% dextrose, without additives, through a separate
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Figure 1. Trial profile. Chart shows flow of patients once entered on study. AmB-d, amphotericin B deoxycholate.
intravenous line by continuous infusion. Administration of
drugs to prevent chills or fever was discouraged on this day;
otherwise, there were no restrictions on the use of any con-
comitant treatment. To reduce nephrotoxicity, all patients re-
ceived an additional 1000 mL of saline every 24 h as standard
care, whenever possible [14–17]. The initial protocol allowed
dose escalation to start on day 3, when renal function remained
stable (i.e., an increase in the serum creatinine level of 10
mM in 48 h was observed) and when infusion-related side effects
were tolerated by the patient. The daily dose was increased by
10 mg every other day, as long as the renal function remained
stable (i.e., an increase in the serum creatinine level of 10
mM in 48 h was observed) and the drug was still tolerated. For
practical reasons, the dose was increased by the same amount
of drug, regardless of the weight of the patient; thus, the time
required to achieve the target dosage varied among patients.
After the inclusion of 10 patients with a target dosage of 1.5
mg/kg/day, an interim analysis showed that dose escalation was
unproblematic in each patient. As a result, the protocol was
modified to allow a target dosage of 1.75 mg/kg/day and dose
escalation (again, starting on day 3) by 10 mg per day every
day, provided that the serum creatinine level did not increase
more than 10 mM per day. After 9 patients were treated with
1.75 mg/kg, another interim analysis again confirmed that dose
escalation was unproblematic, and a maximum dosage of 2.0
mg/kg/day was targeted. Potassium was supplemented by con-
tinuous infusion to maintain a plasma level of 3.6 mM. So-
dium bicarbonate was administered to keep the plasma level
16 mM either by bolus or continuous administration. All but
2 patients were treated with antifungal monotherapy. Of these
2 patients, one was treated with a combination of AmB-d and
flucytosine because of cryptococcal meningitis, and the other
received AmB-d in combination with caspofungin and flucy-
tosine because of life-threatening aspergillosis of the maxilar
sinus, with orbital and cerebral invasion; both patients were
included in the 2 mg/kg dose group.
Adverse drug-related effects and outcome measures. The
occurrence of chills, rigors, vomiting, and feverish reactions
was monitored prospectively, and patients were interviewed
regularly to find which side effects were experienced. We also
evaluated nursing charts for any other adverse reactions. Body
temperature was measured with tympanic membrane ther-
mometers at least twice daily; fever was defined as a core tem-
perature of 139.3C [7]. Sodium, potassium, and creatinine
levels were measured daily; magnesium and bicarbonate levels
were measured every other day; and hematologic parameters
and levels of C-reactive protein, liver transaminases, alkaline
phosphatase, bilirubin, calcium, albumin, total cholesterol, and
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Table 2. Dosage data for patients who received amphotericin B deoxycholate (AmB-d) therapy and concomitant nephrotoxic drugs.
Regimen, dosage data or drug
All patients
(n p 33)
AmB-d target dosage group
1.5 mg/kg/day
(n p 14)
1.75 mg/kg/day
(n p 9)
2 mg/kg/day
(n p 10)
AmB-d therapy, median value (range)
Maximum daily dose, mg/kg 1.72 (1.41–2.28) 1.49 (1.41–1.56) 1.74 (1.64–1.85) 2.08 (1.96–2.28)
Cumulative dose, mg 2245 (370–7995) 1245 (370–3530) 3234 (1290–7185) 2871 (1250–7995)
Cumulative dose, mg/kg 34.93 (6.2–123.24) 19.84 (6.2–55.16) 49.68 (17.43–123.24) 44.29 (21.2–120.23)
Duration of therapy, days 22 (7–72) 14 (7–42) 32 (14–72) 25 (8–67)
Concomitant nephrotoxic drugs,
no. of patients
Aminoglycosides 7 3 2 2
Glycopeptides 15 7 4 4
Diuretics 4 2 1 1
Cyclosporine 2 1 1 —
triglycerides were measured at least on a weekly schedule. All
measurements were done in accordance with standard labo-
ratory procedures. Experienced toxicities were rated according
to the National Cancer Institute Common Toxicity Criteria
(available at: http://ctep.cancer.gov/reporting/ctc.html). Effi-
cacy was monitored for overall mortality and mortality due to
invasive fungal infections.
Statistical analysis. All patients who completed dose es-
calation to 1.5 mg/kg/day were included in the final analysis.
Results are presented as median values and ranges. Nonpara-
metric statistical tests were used throughout. Continuous vari-
ables were compared using the Kruskal-Wallis 1-way analysis of
variance test or the Friedman test with Dunn’s multiple com-
parisons post test, as appropriate, whereas discontinuous varia-
bles were compared with the x2 test for trend. Statistical calcu-
lations were done using InStat software, version 3.05 (GraphPad).
was considered to be statistically significant.P ! .05
RESULTS
Study population. A total of 43 patients were enrolled in the
study (figure 1). Ten patients did not complete dose escalation
from 1 mg/kg/day to 1.5 mg/kg/day: 3 patients died during
AmB-d dose escalation of progression of underlying disease
(acute myeloid leukemia in all patients); 5 patients discontinued
use of the drug because the WBC count recovered, rendering
AmB-d therapy unnecessary; and dose escalation was errone-
ously stopped prematurely in 2 patients (because of protocol
violation), although no organ dysfunction developed and the
drug was well tolerated. Thus, 33 patients, of whom 31 were
neutropenic at study entry, were assessable for analysis; their
demographic characteristics and baseline laboratory parameters
are shown in table 1. Invasive fungal infections were verified
by culture for 9 patients (4 patients had pulmonary infections
due to Aspergillus species, 3 had aspergillosis of the maxillary
sinus and the lung, 1 had disseminated histoplasmosis, and 1
had disseminated Cryptococcus neoformans infection).
Duration of therapy. As shown in table 2, the duration
of antifungal therapy varied considerably, ranging from 7 to 72
days. For the initial 10 patients, dose escalation to 1.5 mg/kg/
day necessitated a median of 8.5 days (range, 6–13 days). Dose
escalation was possible without delay in 8 patients. In 2 patients
who were concomitantly receiving aminoglycosides, an increas-
ing serum creatinine level resulted in delays of 2 and 3 days
until the target dose was reached. With the modified protocol,
dose escalation was more rapid: a median of 5 days (range,
4–8 days) was required for the remaining patients to achieve
a daily dose of 1.5 mg/kg, and dose escalation was possible
without any delay for all of these patients. Dose-escalation re-
quired 9 days (range, 7–20 days) in the 1.75 mg/kg/day group.
In 1 patient, there was a 10-day delay because of increasing
liver enzyme values, and, in another patient, intended dose
escalation to 1.75 mg/kg/day was discontinued at 1.5 mg/kg/
day because of increasing creatinine levels (see “Laboratory
parameters” section below). Dose escalation was completed in
8 days (range, 7–14 days) in the 2 mg/kg/day group, and it was
delayed in only 2 patients because of nephrotoxicity during
concomitant use of flucytosine and aminoglycosides.
After dose escalation was completed, antifungal therapy was
maintained for 1–34 days in the 1.5 mg/kg/day group, 1–65
days in the 1.75 mg/kg/day group, and 1–59 days in the 2.0
mg/kg/day group. The daily AmB-d dose had to be reduced
after completion of dose escalation in 4 patients: in 3 patients,
aminoglycosides were used concomitantly, whereas, in 1 pa-
tient, vancomycin was additionally administered.
Infusion-related reactions. The use of drugs to prevent
chills or fever was discouraged on day 1 of antifungal therapy
to assess infusion-related toxicities. Of the 727 infusions ad-
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Table 3. Summary of data on nephrotoxicity for recipients of amphotericin B deoxycholate (AmB-d).
Variable
All patients
(n p 33)
AmB-d target dosage group
1.5 mg/kg/day
(n p 14)
1.75 mg/kg/day
(n p 9)
2 mg/kg/day
(n p 10)
Creatinine clearance, mL/min
At baseline 102.2 (61.6–195.8) 107.6 (61.6–195.8) 106.7 (70.0–156.6) 103.2 (79.4–115.9)
At end of dose escalation 86.4 (31.2–119.3)b 86.6 (54.4–119.3) 83.0 (31.2–97.2) 87.2 (62.6–116.3)
At end of AmB-d therapy 72.5 (24.0–116.8)c 79.4 (44.3–116.8) 72.5 (26.8–83.8)a 66.1 (24.0–116.4)b
Potassium supplementation, mmol per day
At baseline 80 (0–330) 70 (0–200) 80 (0–200) 60 (40–330)
At 1.5 mg/kg/day dosing 200 (80–380) 210 (120–360)c 240 (100–380)b 190 (80–360)a
At 1.75 mg/kg/day dosing 250 (80–420)c — 250 (100–420)c 225 (80–360)c
At 2.0 mg/kg/day dosing 225 (80–360)c — — 225 (80–360)c
Intravenous fluid administration, mL per day
At baseline 3800 (1500–7520) 3150 (1500–4900) 4400 (2600–6400) 3800 (1500–7520)
At 1.5 mg/kg/day dosing 4200 (2200–6000) 4100 (2800–4700)a 4450 (2850–5150) 4050 (2200–6000)
At 1.75 mg/kg/day dosing 4200 (3200–6100) — 4350 (3250–5300) 4200 (3200–6100)
At 2.0 mg/kg/day dosing 4425 (3800–6150)a — — 4425 (3800–6150)a
NOTE. Data are median (range).
a .P ! .05
b .P ! .01
c , compared with the corresponding baseline value.P ! .001
ministered, 129 (18%) were associated with infusion-related
reactions. Seventeen patients (52%) had chills and/or rigor on
day 1 or 2. Nausea was noted in 7 patients (21%). Itching was
reported by 3 patients (9%). A febrile reaction was noted during
treatment in 1 patient. In 1 patient, respiratory decompensation
occurred after 10 days of antifungal therapy and was most likely
due to the large quantity of infusion that was administered.
Laboratory parameters. The course of renal function dur-
ing dose escalation and follow-up is shown in table 3. Twenty-
seven patients (82%) had a decrease in creatinine clearance
while receiving AmB-d therapy. Sixteen patients (48%) had
values that were 1.5 times less than the baseline value, 7 (44%)
of whom were in the 1.5 mg/kg/day group, 4 (25%) of whom
were in the 1.75 mg/kg/day group, and 5 (31%) of whom were
in the 2.0 mg/kg/day group ( ). Five patients (15%) hadPp .36
a value 2 times less than the baseline value: 1 in the 1.5 mg/
kg/day group, 3 in the 1.75 mg/kg/day group, and 1 in the 2.0
mg/kg/day group ( ). In 1 patient, the serum creatininePp .42
level increased abruptly (from 79 to 175 mM), necessitating
discontinuation of dose escalation. Afterwards, the creatinine
level persisted at 166–199 mM until AmB-d therapy was dis-
continued. In the remaining patients, the range of peak serum
creatinine levels was 52–196 mM during the study. After com-
pletion of dose escalation, creatinine clearance levels decreased
only slightly further, but the deceases were clinically insignif-
icant in most patients (table 3), with only 1 patient (in the 2.0
mg/kg/day group) experiencing a significant increase in the
serum creatinine level while developing septic shock due to
Enterococcus faecalis. No patient required hemodialysis. A dose-
dependent increase in the daily required potassium supple-
mentation was found, and, similarly, the daily amount of in-
travenous fluid administration increased with increasing daily
AmB-d doses (table 3). In addition, supplementation with so-
dium bicarbonate was necessary for 21 patients (64%) because
of the development of tubular acidosis (7 [33%] of these 21
patients were in the 1.5 mg/kg/day group, 6 [29%] were in the
1.75 mg/kg/day group, and 8 [38%] were in the 2.0 mg/kg/day
group [ ]). Hypomagnesemia requiring magnesiumP ! .0001
substitution occurred in 24 patients (73%), 10 (42%) of whom
were in the 1.5 mg/kg/day group, 6 (25%) of whom were in
the 1.75 mg/kg/day group, and 8 (33%) of whom were in the
2.0 mg/kg/day group ( ).Pp .42
Changes in liver enzyme levels are presented in table 4. Gen-
erally, these changes were mild and considered to be clinically
insignificant. There was, however, a significant increase in the
serum alkaline phosphatase level in the overall population (ta-
ble 4).
Only 1 patient (who was in the 1.75 mg/kg/day group) had
grade 3 hepatotoxicity. This patient, who had acute myeloid
leukemia, had normal liver function before antifungal treat-
ment was started. While he was receiving the drug at a dose
of 1.2 mg/kg, asymptomatic elevation of the liver enzyme level
was noted. However, dose escalation was continued, because
the patient’s liver function stabilized and remained at in-
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Table 4. Summary of data on hepatotoxicity among recipients of amphotericin B deoxycholate
(AmB-d).
Laboratory valuea
All patients
(n p 33)
AmB-d target dosage group
1.5 mg/kg/day
(n p 14)
1.75 mg/kg/day
(n p 9)
2 mg/kg/day
(n p 10)
AST, U/L
At baseline 20 (6–105) 20.5 (6–105) 26 (7–92) 18 (7–69)
At end of dose escalation 19 (7–368) 19 (7–46) 16 (9–368) 25 (9–63)
At end of AmB-d therapy 24 (7–298) 23.6 (7–42) 13 (8–298) 32 (14–118)
ALT, U/L
At baseline 31 (8–158) 26.5 (8–158) 22 (9–118) 44 (10–83)
At end of dose escalation 22 (6–220) 28 (6–167) 17 (13–220) 29 (13–83)
At end of AmB-d therapy 38 (8–284) 40 (11–138) 18 (8–284) 62 (19–197)
AP, U/L
At baseline 74 (16–322) 92 (33–211) 81 (29–299) 69.5 (16–322)
At end of dose escalation 135 (36–731)b 86 (42–385) 115 (36–731) 178 (23–339)
At end of AmB-d therapy 140 (36–1457)c,d 119 (43–371) 121 (36–300) 205 (60–1457)b
Total bilirubin, mM
At baseline 15 (3–40) 14 (9–22) 15 (6–28) 16.5 (3–40)
At end of dose escalation 15 (3–23) 14 (6–17) 20 (9–25) 12 (3–23)
At end of AmB-d therapy 13 (7–49) 10 (7–18) 15 (10–34) 27 (9–49)
NOTE. Data are median (range). ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate
aminotransferase.
a Normal levels and ranges for laboratory values are as follows: AST, !35 IU/L; ALT, !35 IU/L; AP, 30–115 U/L; and
total bilirubin, !25 mM.
b .P ! .05
c , compared with the corresponding baseline value.P ! .001
d , compared with the value at end of dose escalation.P ! .05
creased levels during the whole course of treatment. The al-
anine aminotransferase levels were 111–368 U/L (baseline, 53
UL), the aspartate aminotransferase levels were 83–284 U/L
(baseline, 27 U/L), and the alkaline phosphatase levels were
300–731 U/L (baseline, 299 U/L). All levels returned to nor-
mal after drug discontinuation. Reexposure to a low dose of
AmB-d prompted a rapid increase in the levels with a sub-
sequent return to normal levels when the medication was
definitely discontinued.
Outcome. Twenty-four patients (73%) were alive at the
end of treatment. Four patients in the 1.5 mg/kg/day group, 2
patients in the 1.75 mg/kg/day group, and 3 patients in the 2.0
mg/kg/day group died during the treatment period ( ).Pp .50
Death was considered to be unrelated to fungal infection in all
of these patients. However, invasive fungi were found at autopsy
in 3 patients (2 from the 1.5 mg/kg/day group and 1 from the
1.75 mg/kg/day group). Two months after the termination of
antifungal therapy, 22 patients (67%) were still alive. Two pa-
tients died of progression of disease unrelated to fungal infec-
tion (acute leukemia in both).
DISCUSSION
Animal studies and limited results from clinical trials have dem-
onstrated the dose-dependent efficacy of AmB [8–11], provid-
ing the rationale for the administration of the maximum tol-
erated doses of the drug to severely ill patients [18]. Two
different strategies are currently used to reduce dose-limiting,
infusion-related side effects and organ dysfunction. In the first,
lipid formulations of AmB are used, and results of dose-
escalation trials involving liposomal AmB have recently been
published [19, 20]. However, these formulations’ enormous
costs may limit widespread use, and it remains unclear whether
they are more effective than conventional AmB-d. Liposomes
profoundly alter the pharmacokinetics of AmB [21], and in
vitro studies and experimental animal models indicate that lipid
formulations of AmB have significantly lower activity than does
AmB-d [22, 23]. Accordingly, a mean daily dose of 3 mg/kg
of liposomal AmB was found to have a therapeutic efficacy
comparable to that of a mean daily dose of 0.6 mg/kg of con-
ventional AmB-d in a large study of 687 patients with persistent
fever and neutropenia [10].
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Table 5. Frequency of infusion-related side effects and nephrotoxicity during receipt of treatment
with liposomal amphotericin B (AmB), conventionally administered AmB deoxycholate (AmB-d), and
continuously infused AmB-d (CI AmB-d).
Study, treatment arm
No. of
subjects
Chills or
rigors on
day 1 of
treatment Nausea
Creatinine concentration,
multiple of baseline value
1.5 2.0 3.0
Walsh et al. [10]
Liposomal AmB 343 63 (18.4) 42 (12.2) 99 (29) 65 (19) 27 (8)
AmB-d 344 187 (54.4) 35 (10.2) 168 (49) 117 (34) 58 (17)
Eriksson et al. [7]
CI AmB-d 40 5 (13) NA 13 (33) 6 (15) 0
Rapid infusion of AmB-d 40 21 (53) NA 23 (58) 11 (28) 4 (10)
Present report: dose escalation
of CI AmB-da
1.5 mg/kg/day 14 6 (43)b 3 (21) 4 (29) 1 (7) 0
1.75 mg/kg/day 9 6 (67)b 1 (11) 1 (11) 2 (22) 0
2.0 mg/kg/day 10 1 (10)b 3 (30) 1 (10) 1 (10) 1 (10)
Walsh et al. [19]: dose escalation
of liposomal AmBa
7.5 mg/kg/day 8 3 (38) 0 3 (38) 2 (25) NA
10 mg/kg/day 10 0 1 (10) 5 (50) 3 (30) NA
12.5 mg/kg/day 7 1 (14) 0 4 (57) 3 (43) NA
15 mg/kg/day 19 1 (5) 0 10 (53) 6 (32) NA
NOTE. Data are no. (%) of patients. NA, data not available.
a Treatment arms are defined according to target dosages.
b Data comprise events experienced on day 1 and 2.
In the second approach, AmB-d is administered by contin-
uous infusion. Compared with traditional administration over
2–6 h, continuous drug infusion prevents a majority of infu-
sion-related side effects [6, 7]. Here, we have shown that con-
tinuous infusion of AmB-d in doses that were gradually es-
calated up to 2.0 mg/kg/day is feasible, safe, and well tolerated
in most patients. Although a significant number of patients had
either an infusion-related side effect and/or laboratory evidence
of organ dysfunction, in most cases, these adverse events were
generally mild and could be controlled by supportive measures.
Table 5 shows the frequency of infusion-related side effects
and the degree of nephrotoxicity observed in the present study,
compared with those observed in studies of treatment with
standard dose and dose-escalated liposomal AmB, convention-
ally administered AmB-d, and continuously infused AmB-d at
a dose of 1 mg/kg [7, 10, 19]. Overall, the degree of nephro-
toxicity and the incidence of infusion-related side effects
(chills, rigor, or nausea) appear comparable to those obtained
with liposomal AmB [10, 19, 20] and lower doses of contin-
uously infused AmB-d [6, 7]. Infusion-related side effects
occurred early (mostly within the first few hours of therapy)
and did not recur later in the course of dose escalation. In-
fusion-related toxicities may be mediated by cytokines [24],
and continuous infusion may be better tolerated because of
a delayed induction/release of such mediators, as has been
suggested elsewhere [6, 7].
AmB affects both glomerular and tubular structures. Acute
AmB-induced vasoconstriction of the intrarenal arterioles de-
creases renal blood flow and the glomerular filtration rate, and
this effect can be promoted by concurrent hyponatremia. Ac-
cordingly, saline infusion improves renal function and increases
AmB tolerance [25]. Therefore, our patients received an ad-
ditional 1000 mL of saline per day whenever this was tolerated,
and in only 1 patient were there respiratory problems caused
by significant hyperhydration. Although most of the drug’s
adverse effects involved renal function, a 12-fold decrease in
creatinine clearance was observed in only 5 patients (15%).
This is remarkable, because many patients concomitantly re-
ceived nephrotoxic agents, and 2 of the patients developed a
sepsis syndrome with multi-organ failure, which, itself, may
have contributed to renal dysfunction. In a recent study, cy-
closporine use significantly decreased the level of serum cre-
atinine clearance in patients treated with a continuous infusion
of AmB-d [26]. However, impairment of renal function was
reversible and clinically tolerated in all cases. In the present
study, both patients who received concomitant cyclosporine
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therapy completed AmB-d dose escalation without delay. Nev-
ertheless, close monitoring of patients who are concomitantly
receiving nephrotoxic medications is warranted.
A second nephrotoxic mechanism is a directly toxic effect
on renal tubular cells, resulting in enhanced membrane per-
meability with subsequent intracellular and tubular loss of elec-
trolytes, mainly potassium and magnesium. Previous studies
have shown that the risk of renal insufficiency associated with
AmB-d increases with preexisting renal dysfunction, hypovo-
lemia, high cumulative doses of AmB, duration of therapy, and
concomitant use of diuretics or other nephrotoxic drugs [7,
27]. However, there was little additional glomerular nephro-
toxicity in patients who received daily doses of AmB-d up to
1.5–2.0 mg/kg, compared with those who received daily doses
of 1.0 mg/kg (table 5). Although there was no clear evidence
of a dose-dependent glomerular dysfunction in this study, there
was a dose-dependent effect on tubular dysfunction, which was
evidenced by a step-wise increase in the daily requirement for
supplemented potassium and in the percentage of patients who
required sodium bicarbonate for compensation of tubular ac-
idosis. These findings suggest that the renal tubular epithelium
may be more sensitive to high dosages of AmB-d than are cells
that regulate renal blood flow and glomerular filtration. Thus,
high-dose AmB-d therapy warrants a meticulous approach that
involves monitoring of pH and serum electrolyte levels, espe-
cially levels of potassium, bicarbonate, and magnesium; such
therapy may require extensive supplementation and daily ad-
justments to treatment.
In contrast to liposomal AmB, AmB-d therapy is infre-
quently associated with the side effect hepatotoxicity [10, 28,
29]. Increases in bilirubin and liver transaminase levels were
mild, asymptomatic, and clinically insignificant in all but 1
patient, whereas an elevation of serum alkaline phosphatase
levels was noted in the overall study group. However, some
of these changes may have been related to effects of che-
motherapy, preparative regimens for bone marrow transplan-
tation, and intercurrent septic events, rather than receipt of
AmB-d.
Several novel antifungal agents have emerged in recent years
that offer useful alternatives to AmB [18]. For example, itra-
conazole has a efficacy similar to that of AmB-d at a mean
daily dose of 0.71 mg/kg in patients with persistent fever and
neutropenia [30], and voriconazole was even more effective
than AmB-d in patients with invasive aspergillosis; however, in
the latter study, the mean daily dose of AmB-d was 0.97 mg/
kg, and there was a wide range of doses administered (0.27–1.5
mg/kg/day) [31]. Assuming a dose-dependent efficacy of AmB,
it is conceivable that higher doses of AmB-d could result in
better clinical outcome, but this needs to be tested further. It
is important to note that the present study was not sufficiently
powered to assess clinical efficacy, and no conclusions regarding
therapeutic results should therefore be drawn from this trial.
However, our experience with gradually increased daily doses
of AmB-d given by continuous infusion, as reported herein,
may offer a base for future, carefully designed comparative trials
aimed at defining the optimal daily dose of AmB-d and elu-
cidating whether dose-escalated AmB-d has an improved ef-
ficacy. Given the low additional toxicity of stepwise-escalated
AmB-d therapy administered by continuous infusion, it seems
justified to use this regimen for comparison with lipid for-
mulations of AmB or one of the newer antifungal agents in
larger comparative trials.
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